Controlled clinical trials in patients with pulmonary arterial hypertension (PAH): treatment effects
| Trial [ref.] | ||||||
| Terbogrel | Treprostinil | Bosentan: pilot | BREATHE-1 | ALPHABET | AIR | |
| 27 | 28 | 31 | 32, 62 | 29 | 30 | |
| Treatment effect on the primary end-points | ||||||
| 6-min walk distance mean change m | ||||||
| Overall population | 0 | 16# | 76 | 44 | 25 | 36 |
| PPH | 0 | 19# | 76 | 52 | 45 | 57 |
| Haemodynamic parameters (overall population) | No change | Improved | Improved | Improved¶ | No change | Improved+ |
| Clinical events (overall population) | Increased | Reduced | Reduced | Reduced | No change | Reduced |
BREATHE-1: Bosentan Randomised trial of Endothelin Antagonist Therapy for PAH
ALPHABET: Arterial Pulmonary Hypertension and Beraprost European Trial
AIR: Aerosolized Iloprost Randomised study
PPH: primary pulmonary hypertension
#: median change
¶: improvement in Doppler-derived cardiac index and other echocardiographic parameters
+: only pulmonary vascular resistance improved in pre-inhalation period and a more consistent improvement of other parameters is observed in postinhalation period